Search Results

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction (MARAVIROC)

• Authors : National Heart, Lung, and Blood Institute (NHLBI)

• Source: A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction Immunosuppression

Record details

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

• Source: A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and

Record details

The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke (CAMAROS)

• Authors : University Health Network, Toronto; University of California, Los Angeles; Sunnybrook Health Sciences Centre

• Source: The CAMAROS Trial: The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After StrokeBen Assayag E, Korczyn AD, Giladi N, Goldbourt

Record details

Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival

• Authors : Bárbara Mora-Lagos; María Elena Reyes; Lorena Lobos-Gonzalez

Subjects: Gastric cancer (GC); Cisplatin (CDDP); Chemoresistance

• Source: Biological Research, Vol 58, Iss 1, Pp 1-13 (2025)

Record details

Maraviroc Efficacy for Hepatitis C (MAVERIC)

• Authors : ViiV Healthcare; Lydia Tang, Assistant Professor

• Source: A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C

Record details

Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial.

• Authors : Tene O; Department of Psychiatry, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.; Department of Psychiatry, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Subjects: Maraviroc*/Maraviroc*/Maraviroc*/administration & dosage ; Maraviroc*/Maraviroc*/Maraviroc*/therapeutic use ; CCR5 Receptor Antagonists*/CCR5 Receptor Antagonists*/CCR5 Receptor Antagonists*/therapeutic use

• Source: BMC neurology [BMC Neurol] 2024 Jun 06; Vol. 24 (1), pp. 190. Date of Electronic Publication: 2024 Jun 06.Publisher: BioMed Central Country of Publication: England NLM ID: 100968555 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2377

Record details

High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells.

• Authors : De La Torre Tarazona E; Infectious Diseases Department, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), University Hospital Ramón y Cajal, Madrid, Spain. .; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. .

Subjects: Maraviroc*/Maraviroc*/Maraviroc*/pharmacology ; CD4-Positive T-Lymphocytes*/CD4-Positive T-Lymphocytes*/CD4-Positive T-Lymphocytes*/metabolism ; CD4-Positive T-Lymphocytes*/CD4-Positive T-Lymphocytes*/CD4-Positive T-Lymphocytes*/drug effects

• Source: Scientific reports [Sci Rep] 2024 Jun 17; Vol. 14 (1), pp. 13980. Date of Electronic Publication: 2024 Jun 17.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Maraviroc enhances Bortezomib sensitivity in multiple myeloma by inhibiting M2 macrophage polarization via PI3K/AKT/RhoA signaling pathway in macrophages.

• Authors : Yang, Huiye¹ (AUTHOR); He, Yuchan² (AUTHOR); Qu, Fujun¹ (AUTHOR)

• Source: Cell Division. 2/14/2025, Vol. 20 Issue 1, p1-13. 13p.

Record details

Maraviroc in Patients With Moderate and Severe COVID-19

• Source: Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2

Record details

Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

• Authors : German Cancer Research Center; Niels Halama, Principal Investigator, Head of Department Translational Immunotherapy

• Source: LUMINESCENCE-001 Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer

Record details